KINTARA THERAPEUTICS INC (KTRA) Stock Price, Quote, News and Overview
NASDAQ:KTRA - Nasdaq - US49720K2006 - Common Stock - Currency: USD
KTRA Quote, Performance and Key Statistics
0.2154
-0.01 (-6.31%)
The current stock price of KTRA is 0.2154 USD. In the past month the price increased by 18.55%. In the past year, price decreased by -94.63%.
KTRA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About KTRA
Company Profile
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 2 full-time employees. The company went IPO on 2016-07-12. The firm's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. The company has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study. VAL-083 is also used for various other indications.
Company Info
KINTARA THERAPEUTICS INC
9920 Pacific Heights Blvd, Suite 150, Suite 200
San Diego CALIFORNIA 92130 US
CEO: Saiid Zarrabian
Employees: 2
Company Website: https://www.kintara.com/
Phone: 18583504364
KINTARA THERAPEUTICS INC / KTRA FAQ
What is the stock price of KINTARA THERAPEUTICS INC today?
The current stock price of KTRA is 0.2154 USD. The price decreased by -6.31% in the last trading session.
What is the ticker symbol for KINTARA THERAPEUTICS INC stock?
The exchange symbol of KINTARA THERAPEUTICS INC is KTRA and it is listed on the Nasdaq exchange.
On which exchange is KTRA stock listed?
KTRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KINTARA THERAPEUTICS INC stock?
6 analysts have analysed KTRA and the average price target is 14.28 USD. This implies a price increase of 6529.53% is expected in the next year compared to the current price of 0.2154. Check the KINTARA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KINTARA THERAPEUTICS INC worth?
KINTARA THERAPEUTICS INC (KTRA) has a market capitalization of 11.99M USD. This makes KTRA a Nano Cap stock.
How many employees does KINTARA THERAPEUTICS INC have?
KINTARA THERAPEUTICS INC (KTRA) currently has 2 employees.
What are the support and resistance levels for KINTARA THERAPEUTICS INC (KTRA) stock?
KINTARA THERAPEUTICS INC (KTRA) has a support level at 0.18 and a resistance level at 0.24. Check the full technical report for a detailed analysis of KTRA support and resistance levels.
Should I buy KINTARA THERAPEUTICS INC (KTRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KTRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KTRA, evaluating the profitability, health, valuation and growth aspects
- KINTARA THERAPEUTICS INC (KTRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KINTARA THERAPEUTICS INC (KTRA) Sales and EPS estimates to see what analysts future expectations are.
- KINTARA THERAPEUTICS INC (KTRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KINTARA THERAPEUTICS INC (KTRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- KINTARA THERAPEUTICS INC (KTRA) Stock Chart to make your own analysis
- KINTARA THERAPEUTICS INC (KTRA) Latest news and press-releases to stay up to date.
Does KINTARA THERAPEUTICS INC (KTRA) stock pay dividends?
KTRA does not pay a dividend.
When does KINTARA THERAPEUTICS INC (KTRA) report earnings?
KINTARA THERAPEUTICS INC (KTRA) will report earnings on 2024-11-11, after the market close.
What is the Price/Earnings (PE) ratio of KINTARA THERAPEUTICS INC (KTRA)?
KINTARA THERAPEUTICS INC (KTRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.15).
KTRA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to KTRA. When comparing the yearly performance of all stocks, KTRA is a bad performer in the overall market: 96.29% of all stocks are doing better.
KTRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KTRA. While KTRA seems to be doing ok healthwise, there are quite some concerns on its profitability.
KTRA Financial Highlights
Over the last trailing twelve months KTRA reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS increased by 77.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -137.12% | ||
| ROE | -226.35% | ||
| Debt/Equity | 0 |
KTRA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to KTRA. The Buy consensus is the average rating of analysts ratings from 6 analysts.